These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18251152)

  • 1. Budesonide in Crohn's disease: findings of a compassionate-use program.
    Lyckegaard E; Håkansson K; Bengtsson B
    Hepatogastroenterology; 2007; 54(79):2024-7. PubMed ID: 18251152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
    Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
    Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
    Hanauer S; Sandborn WJ; Persson A; Persson T
    Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
    Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
    Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide modified-release capsules.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide for Crohn's disease.
    Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
    de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
    Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
    Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral budesonide in the management of Crohn's disease.
    Hofer KN
    Ann Pharmacother; 2003 Oct; 37(10):1457-64. PubMed ID: 14519035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.
    Miehlke S; Madisch A; Bethke B; Morgner A; Kuhlisch E; Henker C; Vogel G; Andersen M; Meier E; Baretton G; Stolte M
    Gastroenterology; 2008 Nov; 135(5):1510-6. PubMed ID: 18926826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study.
    Miehlke S; Madisch A; Karimi D; Wonschik S; Kuhlisch E; Beckmann R; Morgner A; Mueller R; Greinwald R; Seitz G; Baretton G; Stolte M
    Gastroenterology; 2009 Jun; 136(7):2092-100. PubMed ID: 19303012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
    Abreu MT
    Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
    [No Abstract]   [Full Text] [Related]  

  • 17. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
    Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
    Weigand K; Wagner-Thiessen E; Stolte M
    Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
    Andus T; Gross V; Caesar I; Schulz HJ; Lochs H; Strohm WD; Gierend M; Weber A; Ewe K; Schölmerich J;
    Dig Dis Sci; 2003 Feb; 48(2):373-8. PubMed ID: 12643618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
    Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.